Búsqueda | Portal de Búsqueda de la BVS España

1.

Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.

Raphael Daniela, D B; Russell, N S; van Werkhoven, E; Immink, J M; Westhoff, D P G; Stenfert Kroese, M C; Stam, M R; van Maurik, L M; van Gestel, C M J; van der Weijden, T; Boersma, L J.

Breast Cancer Res Treat; 185(3): 685-695, 2021 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-33099691

2.

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.

van der Noordaa, M E M; van Duijnhoven, F H; Straver, M E; Groen, E J; Stokkel, M; Loo, C E; Elkhuizen, P H M; Russell, N S; Vrancken Peeters, M T F D.

Ann Surg Oncol; 25(6): 1512-1520, 2018 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-29511992

3.

Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design.

Russell, N S; van Werkhoven, E; Schagen, S B.

Support Care Cancer; 25(1): 67-74, 2017 01.

Artículo en Inglés | MEDLINE | ID: mdl-27554211

4.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade, S; Cameron, D; Poortmans, P; Asselain, B; Azria, D; Cardoso, F; A'Hern, R; Bliss, J; Bogaerts, J; Bonnefoi, H; Brain, E; Cardoso, M J; Chibaudel, B; Coleman, R; Cufer, T; Dal Lago, L; Dalenc, F; De Azambuja, E; Debled, M; Delaloge, S; Filleron, T; Gligorov, J; Gutowski, M; Jacot, W; Kirkove, C; MacGrogan, G; Michiels, S; Negreiros, I; Offersen, B V; Penault Llorca, F; Pruneri, G; Roche, H; Russell, N S; Schmitt, F; Servent, V; Thürlimann, B; Untch, M; van der Hage, J A; van Tienhoven, G; Wildiers, H; Yarnold, J; Bonnetain, F; Mathoulin-Pélissier, S; Bellera, C; Dabakuyo-Yonli, T S.

Ann Oncol; 26(5): 873-879, 2015 May.

Artículo en Inglés | MEDLINE | ID: mdl-25725046

5.

Model-Based Selection for Proton Therapy in Breast Cancer: Development of the National Indication Protocol for Proton Therapy and First Clinical Experiences.

Boersma, L J; Sattler, M G A; Maduro, J H; Bijker, N; Essers, M; van Gestel, C M J; Klaver, Y L B; Petoukhova, A L; Rodrigues, M F; Russell, N S; van der Schaaf, A; Verhoeven, K; van Vulpen, M; Schuit, E; Langendijk, J A.

Clin Oncol (R Coll Radiol); 34(4): 247-257, 2022 04.

Artículo en Inglés | MEDLINE | ID: mdl-34996684

6.

A patient decision aid for breast cancer patients deciding on their radiation treatment, no change in decisional conflict but better informed choices.

Raphael, D B; Russell, N S; Winkens, B; Immink, J M; Westhoff, P G; Stenfert Kroese, M C; Stam, M R; Bijker, N; van Gestel, C M J; van der Weijden, T; Boersma, L J.

Tech Innov Patient Support Radiat Oncol; 20: 1-9, 2021 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-34589620

7.

Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria.

Russell, N S; Kunkler, I H; van Tienhoven, G.

Ann Oncol; 26(6): 1043-1044, 2015 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-25851631

8.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade, S; Cameron, D; Poortmans, P; Asselain, B; Azria, D; Cardoso, F; A'Hern, R; Bliss, J; Bogaerts, J; Bonnefoi, H; Brain, E; Cardoso, M J; Chibaudel, B; Coleman, R; Cufer, T; Dal Lago, L; Dalenc, F; De Azambuja, E; Debled, M; Delaloge, S; Filleron, T; Gligorov, J; Gutowski, M; Jacot, W; Kirkove, C; MacGrogan, G; Michiels, S; Negreiros, I; Offersen, B V; Penault Llorca, F; Pruneri, G; Roche, H; Russell, N S; Schmitt, F; Servent, V; Thürlimann, B; Untch, M; van der Hage, J A; van Tienhoven, G; Wildiers, H; Yarnold, J; Bonnetain, F; Mathoulin-Pélissier, S; Bellera, C; Dabakuyo-Yonli, T S.

Ann Oncol; 26(12): 2505-6, 2015 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-26467471

9.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Straver, M E; Rutgers, E J Th; Rodenhuis, S; Linn, S C; Loo, C E; Wesseling, J; Russell, N S; Oldenburg, H S A; Antonini, N; Vrancken Peeters, M T F D.

Ann Surg Oncol; 17(9): 2411-8, 2010 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-20373039

10.

What do patients and health care professionals view as important attributes in radiotherapy decisions? Input for a breast cancer patient decision aid.

Raphael, D B; Ter Stege, J A; Russell, N S; Boersma, L J; van der Weijden, T.

Breast; 49: 149-156, 2020 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-31812074

11.

Risk communication in a patient decision aid for radiotherapy in breast cancer: How to deal with uncertainty?

Raphael, D B; Russell, N S; Immink, J M; Westhoff, P G; Stenfert Kroese, M C; Stam, M R; van Maurik, L M; van den Bongard, H J G D; Maduro, J H; Sattler, M G A; van der Weijden, T; Boersma, L J.

Breast; 51: 105-113, 2020 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-32298961

12.

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. / Neoadjuvante systemische therapie bij het primair operabel mammacarcinoom: meer voordelen dan alleen borstsparende behandeling.

Straver, M E; van Adrichem, J C; Rutgers, E J Th; Rodenhuis, S; Linn, S C; Loo, C E; Gilhuijs, K G; Oldenburg, H S A; Wesseling, J; Russell, N S; Antonini, N; Vrancken Peeters, M T F D.

Ned Tijdschr Geneeskd; 152(46): 2519-25, 2008 Nov 15.

Artículo en Holandés | MEDLINE | ID: mdl-19055260

13.

Defective repair of DNA double-strand breaks and chromosome damage in fibroblasts from a radiosensitive leukemia patient.

Badie, C; Iliakis, G; Foray, N; Alsbeih, G; Pantellias, G E; Okayasu, R; Cheong, N; Russell, N S; Begg, A C; Arlett, C F.

Cancer Res; 55(6): 1232-4, 1995 Mar 15.

Artículo en Inglés | MEDLINE | ID: mdl-7882314

14.

Radiotherapy: the last 25 years.

Russell, N S; Bartelink, H.

Cancer Treat Rev; 25(6): 365-76, 1999 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-10644502

15.

Variability in target volume delineation on CT scans of the breast.

Hurkmans, C W; Borger, J H; Pieters, B R; Russell, N S; Jansen, E P; Mijnheer, B J.

Int J Radiat Oncol Biol Phys; 50(5): 1366-72, 2001 Aug 01.

Artículo en Inglés | MEDLINE | ID: mdl-11483349

16.

Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy.

Russell, N S; Knaken, H; Bruinvis, I A; Hart, A A; Begg, A C; Lebesque, J V.

Radiother Oncol; 30(3): 213-21, 1994 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-8209004

17.

Why is breast cancer so frequent in The Netherlands?

Bruning, P F; Bonfrer, J M; Ansink, A; Russell, N S; de Jong-Bakker, M.

Eur J Surg Oncol; 14(2): 115-22, 1988 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-3360153

18.

Bilateral angiosarcoma of the breast after conservative treatment of bilateral invasive carcinoma: genetic predisposition?

de Bree, E; van Coevorden, F; Peterse, J L; Russell, N S; Rutgers, E J Th.

Eur J Surg Oncol; 28(4): 392-5, 2002 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-12099648

19.

Lack of correlation of human fibroblast radiosensitivity in vitro with early skin reactions in patients undergoing radiotherapy.

Begg, A C; Russell, N S; Knaken, H; Lebesque, J V.

Int J Radiat Biol; 64(4): 393-405, 1993 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-7901301

20.

Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains.

Russell, N S; Arlett, C F; Bartelink, H; Begg, A C.

Int J Radiat Biol; 68(2): 185-96, 1995 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-7658144

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.

Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Model-Based Selection for Proton Therapy in Breast Cancer: Development of the National Indication Protocol for Proton Therapy and First Clinical Experiences.

A patient decision aid for breast cancer patients deciding on their radiation treatment, no change in decisional conflict but better informed choices.

Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

What do patients and health care professionals view as important attributes in radiotherapy decisions? Input for a breast cancer patient decision aid.

Risk communication in a patient decision aid for radiotherapy in breast cancer: How to deal with uncertainty?

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. / Neoadjuvante systemische therapie bij het primair operabel mammacarcinoom: meer voordelen dan alleen borstsparende behandeling.

Defective repair of DNA double-strand breaks and chromosome damage in fibroblasts from a radiosensitive leukemia patient.

Radiotherapy: the last 25 years.

Variability in target volume delineation on CT scans of the breast.

Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy.

Why is breast cancer so frequent in The Netherlands?

Bilateral angiosarcoma of the breast after conservative treatment of bilateral invasive carcinoma: genetic predisposition?

Lack of correlation of human fibroblast radiosensitivity in vitro with early skin reactions in patients undergoing radiotherapy.

Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains.